COVINGTON, Ky.--(BUSINESS WIRE)--Sep 16, 2020--CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization (CRO) announces the acquisition of Clinart, a full-service CRO with nearly 20 years of experience and strong local expertise in the Middle East and Northern Africa (MENA) region. Clinart provides an extensive array of services, from early to late-stage research as well as product support in accordance with global and regional requirements. “We are excited to have Clinart join CTI to create a stronger and more robust global full-service CRO,” remarked Patrick J. Earley, CTI’s Chief International Business Officer. CTI is currently managing more than 20 active COVID-19 trials for treatment and prevention, in addition to work in regenerative medicine, rare diseases and other therapeutic indications. View source version on businesswire.com:https://www.businesswire.com/news/home/20200916005053/en/CONTACT: Media:Allison Schroeder Connaughtonaconnaughton@ctifacts.comKEYWORD: AFRICA UNITED STATES NORTH AMERICA MIDDLE EAST KENTUCKYINDUSTRY KEYWORD: BIOTECHNOLOGY FDA HEALTH PHARMACEUTICAL CLINICAL TRIALSSOURCE: CTI Clinical Trial and Consulting ServicesCopyright Business Wire 2020.

Source: The North Africa Journal September 16, 2020 12:56 UTC